Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 10;57(6):599.
doi: 10.3390/medicina57060599.

Myositis-Related Interstitial Lung Disease: A Respiratory Physician's Point of View

Yuko Waseda  1
Affiliations
Review

Myositis-Related Interstitial Lung Disease: A Respiratory Physician's Point of View

Yuko Waseda. Medicina (Kaunas). .

Abstract

Idiopathic inflammatory myositis (IIM) is an umbrella term for diseases of unknown origin that cause muscle inflammation. Dermatomyositis and polymyositis are IIMs that commonly cause interstitial lung disease (ILD). When a patient presents with ILD, the evaluation of whether the case displays the characteristics of myositis should be determined by interview, physical examination, imaging findings, the measurement of myositis-related antibodies, and the determination of disease severity after diagnosis. Rapidly progressing anti-melanoma differentiation-associated gene 5 antibody-positive ILD may require rapid multi-drug therapy, while anti-aminoacyl tRNA synthetase (ARS) antibody-positive ILD can be treated with anti-inflammatory drugs. Importantly, however, anti-ARS antibody-positive ILD often recurs and sometimes develops into fibrosis. Early diagnosis is crucial for treatment, and we therefore need to clarify the features of myositis associated with ILD and suspect these pathologies early. This section reviews what clinicians need to look for and what findings are evaluated in patients when diagnosing myositis associated with ILD.

Keywords: anti-ARS antibody; anti-MDA5 antibody; dermatomyositis; polymyositis; progressive fibrosing interstitial lung disease; rapid progressive interstitial lung disease.

PubMed Disclaimer

Conflict of interest statement

Yuko Waseda has received honoraria from Nippon Boehringer Ingelheim for lectures.

Figures

Figure 1
Figure 1
Skin manifestations of PM/DM. (a) Heliotrope rash. (b) Gottron’s sign. (c) Nail fold bleeding. (d) Raynaud’s phenomenon. (e) Anti-synthetase syndrome is often associated with mechanic’s hand. (f,g) Anti-MDA5 antibody-positive dermatomyositis is often associated with reverse Gottron’s sign (f), ulceration, and gangrene (g).
Figure 2
Figure 2
CT findings of anti-ARS antibody-positive ILD. (a) Prednisolone was administered, dense shadows along the bronchial vascular bundles improved, and prednisolone was discontinued after about 10 years. (b) Prednisolone and tacrolimus treatment left mild fibrosis after 4 years. (c) Prednisolone and cyclosporine A treatment achieved temporary improvement after 4 months, but fibrosis worsened after about 13 years.
Figure 3
Figure 3
Classification tree for subgroups of adult myositis-related interstitial lung disease (ILD). A patient must first meet the EULAR/ACR classification criteria for inflammatory myopathies (IIM). The patient can then be sub-classified using the classification tree (modified from the figure in Reference [5]). ARS, aminoacyl-tRNA synthetase; ab, antibody; MDA5, melanoma differentiation-associated gene 5; IBM, inclusion body myositis; PM, polymyositis; DM, dermatomyositis; ADM, amyopathic dermatomyositis.
See this image and copyright information in PMC

References

    1. Yoshifuji H., Fujii T., Kobayashi S., Imura Y., Fujita Y., Kawabata D., Usui T., Tanaka M., Nagai S., Umehara H., et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease com-plicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39:233–241. doi: 10.1080/08916930600622884. - DOI - PubMed
    1. Takato H., Waseda Y., Watanabe S., Inuzuka K., Katayama N., Ichikawa Y., Yasui M., Fujimura M. Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia—With or without PM/DM. Respir. Med. 2013;107:128–133. doi: 10.1016/j.rmed.2012.09.005. - DOI - PubMed
    1. Tsuji H., Nakashima R., Hosono Y., Imura Y., Yagita M., Yoshifuji H., Hirata S., Nojima T., Sugiyama E., Hatta K., et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2019;72:488–498. - PubMed
    1. Yamasaki Y., Yamada H., Ohkubo M., Yamasaki M., Azuma K., Ogawa H., Mizushima M., Ozaki S. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myo-pathies and amyopathic dermatomyositis: Experience in a single institute in Japan. J. Rheumatol. 2011;38:1636–1643. doi: 10.3899/jrheum.101002. - DOI - PubMed
    1. Bottai M., Tjärnlund A., Santoni G., Werth V.P., Pilkington C., Visser M., Alfredsson L., Amato A.A., Barohn R.J., Liang M.H., et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their ma-jor subgroups: A methodology report. Ann. RMD Open. 2017;3:e000507. doi: 10.1136/rmdopen-2017-000507. - DOI - PMC - PubMed

MeSH terms